Asensus Surgical, Inc. ASXC
We take great care to ensure that the data presented and summarized in this overview for ASENSUS SURGICAL, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ASXC
View all-
Black Rock Inc. New York, NY3.47MShares$1.21 Million0.0% of portfolio
-
Sv Health Investors, LLC Boston, MA510KShares$178,5490.71% of portfolio
-
Focus Financial Network Inc /Adv Minneapolis, MN38.1KShares$13,3350.0% of portfolio
-
Ifp Advisors, Inc10.5KShares$3,6720.0% of portfolio
-
American Portfolios Advisors Holbrook, NY216Shares$750.0% of portfolio
-
Ica Group Wealth Management, LLC Denver, CO193Shares$670.0% of portfolio
Latest Institutional Activity in ASXC
Top Purchases
Top Sells
About ASXC
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Insider Transactions at ASXC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 22
2024
|
Anthony C. J. Fernando President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,611,203
-100.0%
|
-
|
Aug 22
2024
|
David Bruce Milne Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
619,884
-100.0%
|
-
|
Aug 22
2024
|
Richard C Pfenniger Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
189,417
-100.0%
|
-
|
Aug 22
2024
|
Kevin J Hobert Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,201
-100.0%
|
-
|
Aug 22
2024
|
Elizabeth Kwo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,201
-100.0%
|
-
|
Aug 22
2024
|
William N Starling Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
39,134
-100.0%
|
-
|
Aug 22
2024
|
William N Starling Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,846
-100.0%
|
-
|
Aug 22
2024
|
Andrea Biffi Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,482,008
-100.0%
|
-
|
Aug 22
2024
|
Andrea Biffi Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
492,815
-100.0%
|
-
|
Aug 22
2024
|
Rampertab Shameze EVP, Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
595,372
-100.0%
|
-
|
Apr 21
2024
|
Anthony C. J. Fernando President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
119,429
-5.15%
|
$0
$0.25 P/Share
|
Apr 21
2024
|
Anthony C. J. Fernando President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
271,739
+10.49%
|
-
|
Apr 21
2024
|
Rampertab Shameze EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,638
-9.49%
|
$0
$0.25 P/Share
|
Apr 21
2024
|
Rampertab Shameze EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
81,521
+15.06%
|
-
|
Feb 04
2024
|
Anthony C. J. Fernando President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
484,572
-19.14%
|
$0
$0.27 P/Share
|
Feb 04
2024
|
Anthony C. J. Fernando President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,042,772
+29.18%
|
-
|
Feb 04
2024
|
Rampertab Shameze EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
150,367
-28.44%
|
$0
$0.27 P/Share
|
Feb 04
2024
|
Rampertab Shameze EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
280,909
+34.69%
|
-
|
Dec 14
2023
|
William N Starling Jr Director |
SELL
Open market or private sale
|
Indirect |
18,134
-100.0%
|
$0
$0.28 P/Share
|
Dec 14
2023
|
William N Starling Jr Director |
BUY
Open market or private purchase
|
Indirect |
18,134
+31.67%
|
$0
$0.28 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 1.68M shares |
---|
Sale (or disposition) back to the issuer | 6.22M shares |
---|---|
Payment of exercise price or tax liability | 798K shares |